Department of Oncology, Montefiore Einstein, Bronx, NY; Montefiore Einstein Comprehensive Cancer Center, Bronx, NY.
Department of Oncology, Montefiore Einstein, Bronx, NY; Department of Molecular Pharmacology, Montefiore Einstein, Bronx, NY.
Clin Colorectal Cancer. 2024 Dec;23(4):337-345. doi: 10.1016/j.clcc.2024.08.003. Epub 2024 Aug 24.
Substantial progress is being made in the development of novel therapies directed against colorectal cancer. The discovery of various molecular markers and advances in tumor profiling have facilitated the development of new targeted agents and immunotherapy. Not only have these drugs improved progression-free survival and even overall survival in some cases, but their related outcomes have also raised questions as to how to best combine or sequence therapies for even greater efficacy. Furthermore, we are beginning to understand how these combination therapies may yield for greater therapeutic response for patients with microsatellite stable colorectal cancer for which there is much need for improvement. In this article, we review recent trial data and explore the outcomes of various targeted therapies and immunotherapies for patient with advanced colorectal cancer.
针对结直肠癌的新型治疗方法正在取得重大进展。各种分子标志物的发现和肿瘤分析技术的进步促进了新型靶向药物和免疫疗法的发展。这些药物不仅在某些情况下改善了无进展生存期，甚至总生存期，而且其相关结果也提出了如何最好地组合或序贯治疗以获得更大疗效的问题。此外，我们开始了解这些联合疗法如何为微卫星稳定型结直肠癌患者带来更大的治疗反应，而这些患者非常需要改善。在本文中，我们回顾了最近的试验数据，并探讨了各种针对晚期结直肠癌患者的靶向治疗和免疫治疗的结果。
